1 Pharma Receiving Nice News (NVS)
Motley Fool
NICE reverses position on new use for Novartis' Lucentis
Fierce Pharma
NICE turns down Avastin for breast cancer
Fierce Pharma
U.K. report says NICE drags its feet on drug approvals
Fierce Pharma
NICE sticks with 'no' for GSK's Tyverb/Roche's Herceptin
Pharma Times, UK
News
Motley Fool

